Structure Therapeutics Inc. GPCR
We take great care to ensure that the data presented and summarized in this overview for Structure Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GPCR
Top Purchases
Top Sells
About GPCR
Insider Transactions at GPCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 15
2025
|
Raymond C Stevens CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
340,332
+23.09%
|
-
|
|
Mar 15
2025
|
Jun Yoon CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
170,166
+11.63%
|
-
|
|
Mar 15
2025
|
Xichen Lin CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
80,829
+32.68%
|
-
|
|
Mar 15
2025
|
Yingli Ma CHIEF TECHNOLOGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
63,810
+38.83%
|
-
|
|
Mar 15
2025
|
Ashley Hall Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,048
+30.14%
|
-
|
|
Mar 15
2025
|
Crespo Blas Coll Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
116,988
+34.76%
|
-
|
|
Sep 18
2024
|
Ashley Hall Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,290
+50.0%
|
-
|
|
Sep 18
2024
|
Crespo Blas Coll Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,600
+46.89%
|
-
|
|
Jun 12
2024
|
Raymond C Stevens CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+8.89%
|
$0
$0.44 P/Share
|
|
Jun 10
2024
|
Raymond C Stevens CHIEF EXECUTIVE OFFICER |
SELL
Conversion of derivative security
|
Direct |
555,000
-46.31%
|
-
|
|
Jun 03
2024
|
Xichen Lin CHIEF SCIENTIFIC OFFICER |
SELL
Conversion of derivative security
|
Direct |
106,200
-55.34%
|
-
|
|
Jun 03
2024
|
Xichen Lin CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
106,200
+35.62%
|
$0
$0.34 P/Share
|
|
Mar 15
2024
|
Xichen Lin CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
85,707
+50.0%
|
-
|
|
Mar 15
2024
|
Mark Allen Bach CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,235
+50.0%
|
-
|
|
Mar 15
2024
|
Yingli Ma CHIEF TECHNOLOGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
36,729
+50.0%
|
-
|
|
Mar 15
2024
|
Jun Yoon CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
59,469
+5.03%
|
-
|
|
Mar 15
2024
|
Raymond C Stevens CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
134,682
+10.1%
|
-
|
|
May 10
2023
|
Bvf Partners L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
7,410,518
-100.0%
|
-
|
|
Feb 07
2023
|
Daniel G Welch |
BUY
Conversion of derivative security
|
Indirect |
123,508
+50.0%
|
-
|
|
Feb 07
2023
|
Ramy Farid Director |
BUY
Conversion of derivative security
|
Indirect |
642,245
+16.46%
|
-
|
Last 12 Months Summary
Buy / Acquisition
1.24M
Shares
From
8
Insiders
| Grant, award, or other acquisition | 981K shares |
|---|---|
| Exercise of conversion of derivative security | 256K shares |
Sell / Disposition
661K
Shares
From
2
Insiders
| Conversion of derivative security | 661K shares |
|---|